The effect of mucodentol on covid-19 symptoms

Evaluation of slow release mucoadhesive paste of” Mucodentol “ on symptoms of COVID-19 disease in non infected family members of infected patients by COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200711048076N1

Enrollment

600

Registered

2020-09-05

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19.

Interventions

Intervention 1: Intervention group: All the non-infected family members who live with an infected COVID-19. Every one will receive 3 mucodentol 3% (Khorraman co) tubes for 3 weeks . They will take it

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age over 18 years. Mental and physical ability to use this drug for three weeks. Lack of sensitivity to similar drugs. Existence of a person with COVID -19 in the family. People are aware of time, place and person, are in a natural state mentally and mentally, Be able to communicate verbally for a telephone interview.

Exclusion criteria

Exclusion criteria: Covid-19 infection Drug sensitivity Underlying diseases: Cardiovascular diseases, Diabetes, Immune system deficiency,... Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Severity of dry coughs. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a sore throat. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a shortness of breath. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a myalgia. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of arthralgia. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of fever. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.	—

Measure

Time frame

Severity of dry coughs. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a sore throat. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a shortness of breath. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of a myalgia. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of arthralgia. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.;Severity of fever. Timepoint: At the end of the first - second and third week of medication use. Method of measurement: Phone call, Self-declaration and fill the related questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehruz Farzan

Khoram-Abad University of Medical Sciences

B_farzan41@yahoo.com0098 6633300661-5

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026